Tissue Inhibitor of Metalloproteinase-2 Polymorphisms and Risk for HIV-Associated Neurocognitive Disorder
Table 6
Frequency distribution of TIMP-2 (-418G/C and 303G/A) genotypes in tobacco using HIV patients with and without HAND.
HIV patients with HAND
Genotypes TIMP-2 -418G/C
Tobacco users
Nonusers
value
OR (95% CI)
(%)
(%)
GG
7 (53.8%)
24 (64.9%)
1
(Reference)
GC
4 (30.8%)
11 (29.7%)
0.76
1.27 (0.27-6.03)
CC
2 (15.4%)
2 (5.4%)
0.26
3.96 (0.37-42.62)
Genotypes TIMP-2 303G/A
Tobacco users
Nonusers
value
OR (95% CI)
(%)
(%)
GG
9 (69.2%)
22 (59.5%)
1
(Reference)
GA
4 (30.8%)
13 (35.1%)
0.79
0.81 (0.18-3.65)
AA
0 (0.0%)
2 (5.4%)
NS
—
HIV patients without HAND
Genotypes TIMP-2- 418G/C
Tobacco users
Nonusers
value
OR (95% CI)
(%)
(%)
GG
13 (68.4%)
43 (65.2%)
1
(Reference)
GC
3 (15.8%)
13 (19.7%)
0.96
1.03 (0.22-4.80)
CC
3 (15.8%)
10 (15.2%)
0.72
0.76 (0.17-3.44)
Genotypes TIMP-2 303G/A
Tobacco users
Nonusers
value
OR (95% CI)
(%)
(%)
GG
15 (78.9%)
47 (71.2%)
1
(Reference)
GA
4 (21.1%)
19 (28.8%)
0.56
0.68 (0.19-2.50)
AA
0 (0.0%)
0 (0.0%)
NS
NS
= number of subjects, (%) = frequency of subjects; odds ratios and 95% CIs were derived from logistic regression models comparing the homozygous wild-type genotype (GG genotype for TIMP-2 -418G/C and 303G/A was taken as reference) with other genotypes. Tobacco status in 15 HIV-infected individuals was unknown, therefore excluded from the analysis.
